CLINICAL TRIALS PROFILE FOR ALTACE
✉ Email this page to a colleague
All Clinical Trials for Altace
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00044265 ↗ | Treatment of Pediatric Hypertension With Altace Trial | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 | 2002-07-01 | Ramipril is an ACE inhibitor that has been marketed in the US for the treatment of hypertension since 1991. It has been shown to be effective in reducing both systolic and diastolic blood pressure in adults when used once daily. ACE inhibitors are frequently used to treat hypertension in children, however ramipril has not been extensively tested in children, and information regarding the efficacy and safety would therefore be of benefit to children. This study is designed to demonstrate the efficacy and safety of ramipril in the treatment of hypertension in children ages 6 through 16 years. |
| NCT00044265 ↗ | Treatment of Pediatric Hypertension With Altace Trial | Completed | Pfizer | Phase 4 | 2002-07-01 | Ramipril is an ACE inhibitor that has been marketed in the US for the treatment of hypertension since 1991. It has been shown to be effective in reducing both systolic and diastolic blood pressure in adults when used once daily. ACE inhibitors are frequently used to treat hypertension in children, however ramipril has not been extensively tested in children, and information regarding the efficacy and safety would therefore be of benefit to children. This study is designed to demonstrate the efficacy and safety of ramipril in the treatment of hypertension in children ages 6 through 16 years. |
| NCT00274599 ↗ | PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN | Completed | Boehringer Ingelheim | Phase 4 | 2002-10-01 | Demonstrate that telmisartan 80mg was at least as effective and possibly superior to ramipril 5mg & 10mg in lowering mean ambulatory DBP and SBP during the last 6 hrs of the 24-hr dosing interval in mild-to-moderate hypertensives at the end of 8 and 14 week treatment phases. |
| NCT00281593 ↗ | Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension | Completed | Boehringer Ingelheim | Phase 3 | 2006-04-01 | To identify dose combinations of telmisartan and ramipril that are more effective in reducing diastolic blood pressure than each of the respective monotherapies in patients with Stage I or II hypertension. |
| NCT00389519 ↗ | A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents | Terminated | Pfizer | Phase 3 | 2006-10-01 | The primary purpose of this study is to evaluate the blood pressure lowering effects of ramipril, an FDA-approved drug for the treatment of hypertension in adults, in children and adolescents aged 6 to 16 years with hypertension. |
| NCT00574834 ↗ | Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes | Terminated | King Pharmaceuticals is now a wholly owned subsidiary of Pfizer | Early Phase 1 | 2007-03-01 | The study will be focused on determining the integrated in-vivo mechanisms responsible for Ramipril's effects on delaying type 2 diabetes and restoring normal (blood sugar levels) glycemia in patients with impaired glucose tolerance. Hypothesis - Ramipril effects will delay the onset of type 2 diabetes and restore normal glycemia in patients with impaired glucose tolerance. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Altace
Condition Name
Clinical Trial Locations for Altace
Trials by Country
Clinical Trial Progress for Altace
Clinical Trial Phase
Clinical Trial Sponsors for Altace
Sponsor Name
